| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6487260 | Current Opinion in Biotechnology | 2018 | 7 Pages |
Abstract
Chinese hamster ovary (CHO) cells have been extensively used for industrial production of biotherapeutics. With advances in cell line development and process optimization, production levels of therapeutic proteins using the CHO expression system have increased to beyond 10Â g per liter scale. These high-titer processes could challenge the secretory capacity of CHO cells, which can result in degradation and aggregation of the protein of interest. This review discusses bottlenecks in the secretory pathway of CHO cells that lead to inefficient secretion and aggregation of proteins, and summarizes current strategies to tackle these bottlenecks. In addition, emerging technologies that facilitate better understanding of cellular mechanisms in protein production could provide new avenues to improve the secretion and quality of protein therapeutics.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Yizhou Zhou, Ravali Raju, Christina Alves, Alan Gilbert,